A	a	O	O	O	O
phase	phase	O	O	O	O
I/II	i/ii	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
first-line	first-line	O	O	O	O
therapy	therapy	O	O	O	O
for	for	O	O	O	O
head	head	O	O	OTHERS	I
and	and	O	O	OTHERS	I
neck	neck	O	O	OTHERS	I
cancers	cancers	O	DISEASE	OTHERS	I
:	:	O	O	O	O
preliminary	preliminary	O	O	O	O
results	results	O	O	O	O
.	.	O	O	O	O

Improved	improved	O	O	O	O
outcomes	outcomes	O	O	O	O
among	among	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
head	head	O	O	OTHERS	I
and	and	O	O	OTHERS	I
neck	neck	O	O	OTHERS	I
carcinomas	carcinomas	O	O	OTHERS	I
require	require	O	O	O	O
investigations	investigations	O	O	O	O
of	of	O	O	O	O
new	new	O	O	O	O
drugs	drugs	O	O	O	O
for	for	O	O	O	O
induction	induction	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Preliminary	preliminary	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
an	an	O	O	O	O
Eastern	eastern	O	O	O	O
Cooperative	cooperative	O	O	O	O
Oncology	oncology	O	O	O	O
Group	group	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
single-agent	single-agent	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
Taxol	taxol	CHEMICALS	O	OTHERS	I
;	;	O	O	O	O
Bristol-Myers	bristol-myers	O	O	O	O
Squibb	squibb	O	O	O	O
Company	company	O	O	O	O
,	,	O	O	O	O
Princeton	princeton	O	O	O	O
,	,	O	O	O	O
NJ	nj	O	O	O	O
)	)	O	O	O	O
reported	reported	O	O	O	O
a	a	O	O	O	O
37	37	O	O	O	O
%	%	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
head	head	O	O	OTHERS	I
and	and	O	O	OTHERS	I
neck	neck	O	O	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
paclitaxel/cisplatin	paclitaxel/cisplatin	O	O	O	O
combination	combination	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
used	used	O	O	O	O
successfully	successfully	O	O	O	O
and	and	O	O	O	O
has	has	O	O	O	O
significantly	significantly	O	O	O	O
improved	improved	O	O	O	O
median	median	O	O	O	O
response	response	O	O	O	O
duration	duration	O	O	O	O
in	in	O	O	O	O
ovarian	ovarian	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
initiated	initiated	O	O	O	O
a	a	O	O	O	O
phase	phase	O	O	O	O
I/II	i/ii	O	O	O	O
trial	trial	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
response	response	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
escalating	escalating	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
doses	doses	O	O	O	O
combined	combined	O	O	O	O
with	with	O	O	O	O
fixed-dose	fixed-dose	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
with	with	O	O	O	O
granulocyte	granulocyte	O	O	O	O
colony-stimulating	colony-stimulating	O	O	O	O
factor	factor	O	O	O	O
support	support	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
untreated	untreated	O	O	O	O
locally	locally	O	O	O	O
advanced	advanced	O	O	O	O
inoperable	inoperable	O	O	O	O
head	head	O	O	OTHERS	I
and	and	O	O	OTHERS	I
neck	neck	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

To	to	O	O	O	O
date	date	O	O	O	O
,	,	O	O	O	O
23	23	O	O	O	O
men	men	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
age	age	O	O	O	O
of	of	O	O	O	O
50	50	O	O	O	O
years	years	O	O	O	O
and	and	O	O	O	O
good	good	O	O	O	O
performance	performance	O	O	O	O
status	status	O	O	O	O
have	have	O	O	O	O
entered	entered	O	O	O	O
the	the	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

Primary	primary	O	O	O	O
tumor	tumor	O	DISEASE	OTHERS	I
sites	sites	O	O	O	O
were	were	O	O	O	O
oropharynx	oropharynx	O	O	O	O
,	,	O	O	O	O
10	10	O	O	O	O
patients	patients	O	O	O	O
;	;	O	O	O	O
hypopharynx	hypopharynx	O	O	O	O
,	,	O	O	O	O
four	four	O	O	O	O
;	;	O	O	O	O
larynx	larynx	O	O	O	O
,	,	O	O	O	O
two	two	O	O	O	O
;	;	O	O	O	O
oral	oral	O	O	O	O
cavity	cavity	O	O	O	O
,	,	O	O	O	O
three	three	O	O	O	O
;	;	O	O	O	O
unknown	unknown	O	O	O	O
primary	primary	O	O	O	O
,	,	O	O	O	O
two	two	O	O	O	O
;	;	O	O	O	O
and	and	O	O	O	O
nasal	nasal	O	O	O	O
cavity	cavity	O	O	O	O
and	and	O	O	O	O
parotid	parotid	O	O	O	O
gland	gland	O	O	O	O
,	,	O	O	O	O
one	one	O	O	O	O
each	each	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
20	20	O	O	O	O
patients	patients	O	O	O	O
evaluable	evaluable	O	O	O	O
for	for	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
four	four	O	O	O	O
had	had	O	O	O	O
stage	stage	O	O	O	O
III	iii	O	O	O	O
and	and	O	O	O	O
16	16	O	O	O	O
had	had	O	O	O	O
stage	stage	O	O	O	O
IV	iv	O	O	O	O
disease	disease	O	O	O	O
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
,	,	O	O	O	O
given	given	O	O	O	O
every	every	O	O	O	O
21	21	O	O	O	O
days	days	O	O	O	O
for	for	O	O	O	O
a	a	O	O	O	O
maximum	maximum	O	O	O	O
of	of	O	O	O	O
three	three	O	O	O	O
cycles	cycles	O	O	O	O
,	,	O	O	O	O
consisted	consisted	O	O	O	O
of	of	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
by	by	O	O	O	O
3-hour	3-hour	O	O	O	O
infusion	infusion	O	O	O	O
followed	followed	O	O	O	O
the	the	O	O	O	O
next	next	O	O	O	O
day	day	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
fixed	fixed	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
75	75	O	O	O	O
mg/m2	mg/m2	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
dose	dose	O	O	O	O
levels	levels	O	O	O	O
incorporate	incorporate	O	O	O	O
escalating	escalating	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
doses	doses	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
intrapatient	intrapatient	O	O	O	O
escalations	escalations	O	O	O	O
within	within	O	O	O	O
a	a	O	O	O	O
given	given	O	O	O	O
dose	dose	O	O	O	O
level	level	O	O	O	O
are	are	O	O	O	O
permitted	permitted	O	O	O	O
if	if	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
permits	permits	O	O	O	O
.	.	O	O	O	O

At	at	O	O	O	O
the	the	O	O	O	O
time	time	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
writing	writing	O	O	O	O
,	,	O	O	O	O
dose	dose	O	O	O	O
level	level	O	O	O	O
4	4	O	O	O	O
(	(	O	O	O	O
260	260	O	O	O	O
,	,	O	O	O	O
270	270	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
280	280	O	O	O	O
mg/m2	mg/m2	O	O	O	O
)	)	O	O	O	O
is	is	O	O	O	O
being	being	O	O	O	O
evaluated	evaluated	O	O	O	O
;	;	O	O	O	O
three	three	O	O	O	O
patients	patients	O	O	O	O
from	from	O	O	O	O
this	this	O	O	O	O
level	level	O	O	O	O
are	are	O	O	O	O
evaluable	evaluable	O	O	O	O
.	.	O	O	O	O

With	with	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
doses	doses	O	O	O	O
of	of	O	O	O	O
200	200	O	O	O	O
mg/m2	mg/m2	O	O	O	O
and	and	O	O	O	O
higher	higher	O	O	O	O
,	,	O	O	O	O
granulocyte	granulocyte	O	O	O	O
colony-stimulating	colony-stimulating	O	O	O	O
factor	factor	CHEMICALS	O	OTHERS	I
5	5	CHEMICALS	O	OTHERS	I
micrograms/kg/d	micrograms/kg/d	O	O	O	O
is	is	O	O	O	O
given	given	O	O	O	O
(	(	O	O	O	O
days	days	O	O	O	O
4	4	O	O	O	O
through	through	O	O	O	O
12	12	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
18	18	O	O	O	O
patients	patients	O	O	O	O
evaluable	evaluable	O	O	O	O
for	for	O	O	O	O
response	response	O	O	O	O
,	,	O	O	O	O
seven	seven	O	O	O	O
(	(	O	O	O	O
39	39	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
achieved	achieved	O	O	O	O
a	a	O	O	O	O
complete	complete	O	O	O	O
response	response	O	O	O	O
and	and	O	O	O	O
six	six	O	O	O	O
(	(	O	O	O	O
33	33	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
achieved	achieved	O	O	O	O
a	a	O	O	O	O
partial	partial	O	O	O	O
response	response	O	O	O	O
.	.	O	O	O	O

Three	three	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
no	no	O	O	O	O
change	change	O	O	O	O
and	and	O	O	O	O
disease	disease	O	O	O	O
progressed	progressed	O	O	O	O
in	in	O	O	O	O
two	two	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
overall	overall	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
is	is	O	O	O	O
72	72	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Eleven	eleven	O	O	O	O
responding	responding	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
subsequent	subsequent	O	O	O	O
surgery/radiotherapy	surgery/radiotherapy	O	O	O	O
or	or	O	O	O	O
radical	radical	O	O	O	O
radiotherapy	radiotherapy	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
pathologic	pathologic	O	O	O	O
complete	complete	O	O	O	O
responses	responses	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
achieved	achieved	O	O	O	O
clinical	clinical	O	O	O	O
complete	complete	O	O	O	O
responses	responses	O	O	O	O
.	.	O	O	O	O

Alopecia	alopecia	O	O	OTHERS	I
,	,	O	O	O	O
paresthesias	paresthesias	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
arthralgias/myalgias	arthralgias/myalgias	O	O	O	O
have	have	O	O	O	O
occurred	occurred	O	O	O	O
frequently	frequently	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
with	with	O	O	O	O
one	one	O	O	O	O
exception	exception	O	O	O	O
(	(	O	O	O	O
a	a	O	O	O	O
grade	grade	O	O	O	O
3	3	O	O	O	O
myalgia	myalgia	O	DISEASE	OTHERS	I
)	)	O	O	O	O
they	they	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
grade	grade	O	O	O	O
1	1	O	O	O	O
or	or	O	O	O	O
2	2	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
dose-limiting	dose-limiting	O	O	O	O
hematologic	hematologic	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
seen	seen	O	O	O	O
.	.	O	O	O	O

Paclitaxel/cisplatin	paclitaxel/cisplatin	O	O	O	O
is	is	O	O	O	O
an	an	O	O	O	O
effective	effective	O	O	O	O
first-line	first-line	O	O	O	O
regimen	regimen	O	O	O	O
for	for	O	O	O	O
locoregionally	locoregionally	O	O	O	O
advanced	advanced	O	O	O	O
head	head	O	O	OTHERS	I
and	and	O	O	OTHERS	I
neck	neck	O	O	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
and	and	O	O	O	O
continued	continued	O	O	O	O
study	study	O	O	O	O
is	is	O	O	O	O
warranted	warranted	O	O	O	O
.	.	O	O	O	O

Results	results	O	O	O	O
thus	thus	O	O	O	O
far	far	O	O	O	O
suggest	suggest	O	O	O	O
no	no	O	O	O	O
dose-response	dose-response	O	O	O	O
effect	effect	O	O	O	O
for	for	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
doses	doses	O	O	O	O
above	above	O	O	O	O
200	200	O	O	O	O
mg/m2	mg/m2	O	O	O	O
.	.	O	O	O	O

